DarioHealth misses Q3 revenue estimates

DarioHealth

13/11/2025 11:38

Overview

DarioHealth Q3 2025 revenue declined year-over-year, missing analyst expectations

Net income for Q3 2025 beat analyst estimates despite revenue decline

Operating income for Q3 2025 missed analyst expectations

Outlook

Dario targets $12.4 mln in new business for 2025

Company expects to reach cashflow breakeven by late 2026 to early 2027

Dario's 2026 commercial pipeline stands at $69 mln

Result Drivers

REVENUE DECLINE - Revenue decreased due to transition from one-time revenues to high-margin recurring revenue model

MULTI-CONDITION PLATFORM - Over 50% of new clients chose multi-condition offering, driving adoption

OPERATING EXPENSES REDUCTION - Operating expenses decreased by 31% in first nine months of 2025 due to operational efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$5 mln
$5.67 mln (4 Analysts)
Q3 Net Income
Beat
-$10.50 mln
-$12.44 mln (4 Analysts)
Q3 Operating Income
Miss
-$9.50 mln
-$8.57 mln (3 Analysts)
Q3 Gross Profit
$3 mln
Q3 Operating Expenses
$12.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for DarioHealth Corp is $25.00, about 53% above its November 12 closing price of $11.75

Press Release: ID:nPn9jsvJya

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)